Skip to main content

Shuttle Pharmaceuticals Holdings, Inc.

corporate_fare Company Profile

Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed SHPH - Latest Insights

SHPH
Apr 10, 2026, 5:12 PM EDT
Filing Type: PRE 14A
Importance Score:
8
SHPH
Mar 31, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
9
SHPH
Mar 10, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
SHPH
Mar 09, 2026, 8:00 AM EDT
Filing Type: 424B3
Importance Score:
9
SHPH
Mar 06, 2026, 8:00 AM EST
Source: TMX Newsfile
Importance Score:
9
SHPH
Feb 11, 2026, 5:03 PM EST
Filing Type: S-1/A
Importance Score:
9
SHPH
Feb 10, 2026, 9:59 PM EST
Filing Type: S-1
Importance Score:
9
SHPH
Feb 02, 2026, 5:20 PM EST
Filing Type: 8-K
Importance Score:
8
SHPH
Feb 02, 2026, 8:15 AM EST
Filing Type: 424B3
Importance Score:
8
SHPH
Jan 12, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
8